Guide
Sublingual Semaglutide (ODT) 2026: Price and the Evidence Gap
Sublingual semaglutide is not the budget option. In the only complete ladder we captured it is the most expensive protocol — $165 to $199 a month against $145 to $165 for
Sublingual semaglutide is not the budget option. In the only complete ladder we captured it is the most expensive protocol — $165 to $199 a month against $145 to $165 for the injection. STEP-1 and SELECT studied subcutaneous injection, so bioavailability by a sublingual route is not established by them. The approved oral Wegovy tablet is $149 with its own trial programme.
Is the sublingual form cheaper than the injection?
No. The assumption is widespread and, on the figures we hold, backwards.
| Term | Injectable | Sublingual ODT | Difference |
|---|---|---|---|
| Month-to-month | $165 | $199 | +$34 |
| 3-month | $149 | $185 | +$36 |
| 6-month | $147 | $177 | +$30 |
| 12-month | $145 | $165 | +$20 |
| Twelve-month total | $1,740 | $1,980 | +$240 |
STEP-1 studied subcutaneous injection. SELECT studied subcutaneous injection. Absorption by a sublingual route is a different pharmacokinetic question and is not answered by either trial.
Semaglutide's oral bioavailability is low — the approved oral tablet solves that with an absorption enhancer and a dosing protocol, which is why it exists as a separate approved product rather than as the same drug taken differently. A compounded sublingual preparation is not that product and has no equivalent programme behind it.
This is a convenience format for people who do not want injections. It is not established as equivalent to the injection, and we will not present it as one.
What is the honest case for it?
- Needle avoidance is a real reason. A treatment you will actually take beats one you will not.
- No cold-chain handling at the point of use.
- It is dose-flexible in the same way a compounded vial is.
What it is not is cheaper, and it is not the approved oral route.
What about the approved pill?
| Route | Monthly | Trial result | FDA-approved? |
|---|---|---|---|
| Oral Wegovy tablet | $149 | 15.1% | Yes |
| Foundayo (orforglipron) | $149 | 12.4% | Yes |
| Compounded sublingual semaglutide | $165–$199 | — | No |
Both approved pills cost less than the compounded sublingual and carry their own trial programmes. If a needle-free route is the requirement, that comparison is the one that matters.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What is the salt-form question?
Semaglutide sodium and semaglutide acetate are not the same active ingredient as the base form in Wegovy and Ozempic, and the FDA has said they are not appropriate for compounding. Ask for the exact salt form and concentration in writing. Tirzepatide has no equivalent question.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Is sublingual semaglutide as effective as the injection?
Not established. STEP-1 and SELECT studied subcutaneous injection; absorption by a sublingual route is a different question those trials do not answer.
Is sublingual semaglutide cheaper?
No. On the ladder we captured it is the most expensive protocol — $1,980 over twelve months against $1,740 for the injection.
What is the cheapest needle-free option?
The approved oral Wegovy tablet at $149, which also has its own trial programme reporting 15.1%.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Cheapest FDA-Approved vs Compounded GLP-1 OptionsJournal
- Injectable vs Oral GLP-1 MedicationsComparisons
- Oral Tirzepatide and Sublingual Products: What Evidence Exists?Pillar / Money
- Provider and Study Source LedgerData
- Open GLP-1 Data and Evidence LibraryData
- GLP-1 Tirzepatide Rank: Evidence, Prices, Providers & ToolsCore & Trust
- Cheapest Compounded Tirzepatide: Ongoing Costs ComparedPillar / Money
Related coverage
- What Is Actually in a Compounded GLP-1: Additives, Salt Forms and a Chemistry Problem
- Semaglutide providers compared
- Cheapest semaglutide online
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Oral Tirzepatide and Sublingual Products: What Evidence Exists?
- Ozempic Cost Without Insurance in 2026: Every Route, Priced
- “Ozempic Face”: What It Is, and Why It Is Not Ozempic-Specific
- Peptide Therapy: What Is Approved, What Is Compounded, and What Is Not a Medicine
GLP-1 Tirzepatide Rank. “Sublingual Semaglutide (ODT) 2026: Price and the Evidence Gap.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/compounded-semaglutide-odt-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.